RayKnowChina Research Map
Shortlist0

ZhengzhouZhengzhou University

Henan Cancer Hospital

河南省肿瘤医院

Listed for 14 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Henan Cancer Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌1 paper led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌41 papers led4 open trials led
  3. Hepatocellular carcinoma肝细胞癌34 papers led1 open trial led
  4. Stomach cancer胃癌76 papers led4 open trials led
  5. Retinoblastoma视网膜母细胞瘤0 papers led
  6. Osteosarcoma骨肉瘤19 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  8. Neuroblastoma神经母细胞瘤1 paper led
  9. Ewing sarcoma尤文肉瘤0 papers led
  10. Multiple myeloma多发性骨髓瘤18 papers led
  11. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led
  12. Aplastic anaemia再生障碍性贫血4 papers led
  13. Haemophilia A血友病 A1 paper led
  14. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Hepatoblastoma, Chordoma, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 1 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Zhengzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy technique
Departments in papersRadiation oncology
Papers it led1
  1. A novel automated planning approach for multi-anatomical sites cancer in Raystation treatment planning system.2023Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
All its trials on ClinicalTrials.gov, any status4
  1. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  2. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  3. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  4. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerStatus unknownNCT01074021Study sitePhase 3Start 2009-10
More papers found outside PubMed (not counted)6
  1. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Researchconference-abstract
  2. Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study.2024Journal of Clinical Oncologyconference-abstract
  3. Data from Epstein-Barr Virus Induces Lymphangiogenesis and Lympth Node Metastasis via Upregulation of VEGF-C in Nasopharyngeal Carcinoma2023Venue not listedother
  4. Mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck cancers: A multicenter, open-label, single-arm, phase Ⅰb study.2022Journal of Clinical Oncologyconference-abstract
  5. The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–20192022Figsharedataset
  6. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 41 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 1.4%.

Papers led
41
2021–2025
Trials led
9
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 6620212022: 101020222023: 7720232024: 8820242025: 882025

6 hospitals in Zhengzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07629817

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  2. Recruiting
    Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2022-08
    Registry
    NCT05495152

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  3. Recruiting
    Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
    Phase
    Phase 3
    Started
    2020-04
    Registry
    NCT04280822

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  4. Recruiting
    Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
    Phase
    Phase 3
    Started
    2019-10
    Registry
    NCT04138212

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  5. Recruiting
    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07405151

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Jinan, Xiamen, Xuzhou, Zhengzhou

  6. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  7. Recruiting
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07733830

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou

  8. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  9. Recruiting
    Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06780111

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Hefei, Nanchang, Xiamen, Xuzhou, Zhengzhou

  10. Recruiting
    A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
    Phase
    Phase 1/Phase 2
    Started
    2023-05
    Registry
    NCT05319730

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Shanghai, Xiamen, Xinxiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentSurgeryMolecular markers & genomics
Departments in papersRadiology / nuclear medicineRadiation oncologyMedical oncologyPathology / laboratory medicine
Papers it led41
  1. MR outperformed CT in evaluating RECIST response to neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma.2026European radiology
  2. Prognostic impact of different lymph node staging systems in patients with esophageal squamous cell carcinoma.2026Surgical endoscopy
  3. Recurrence patterns and long-term survival of locally advanced esophageal cancer patients with pathological complete response after different neoadjuvant therapies followed by surgery.2025BMC cancerFree full text
  4. Evaluating the efficacy of adjuvant chemotherapy in cT1b-T2 patients with incidentally discovered positive lymph nodes after esophagectomy for esophageal squamous cell carcinoma: a retrospective cohort study.2025BMC cancerFree full text
  5. Automated segmentation of esophageal squamous cell carcinoma in contrast-enhanced free-breathing 3D-GRE: a comparative study of UNet, nnUNet, and UMamba for tumor delineation.2025BMC medical imagingFree full text
  6. Radiotherapy combined with anlotinib in locoregional recurrent esophageal squamous cell carcinoma after radical surgery: a prospective, Phase II clinical trial.2025British journal of cancerFree full text
  7. Heterogeneity and distribution characteristics of tertiary lymphoid structures predict prognostic outcome in esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  8. Single-cell RNA sequencing reveals adrb1 as a sympathetic nerve-regulated immune checkpoint driving T cell exhaustion and impacting immunotherapy in esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  9. Optimal lymph node dissection thresholds for early-stage esophageal squamous cell carcinoma: a retrospective multicenter study.2025Surgical endoscopy
  10. Consolidation Chemotherapy Provided Survival Benefit for Esophageal Squamous Cell Carcinoma Patients Who Underwent Concurrent Chemoradiotherapy Lower Than 60 Gy.2025Thoracic cancerFree full text
  11. Multiple diffusion models for predicting pathologic response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy.2024Abdominal radiology (New York)
  12. Neoadjuvant Chemotherapy or Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  13. Consolidation chemotherapy after definitive concurrent chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma: a multicenter non-inferiority phase III randomized clinical trial.2024BMC cancerFree full text
  14. Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial.2024Cancer communications (London, England)RCTFree full text
  15. Intravoxel incoherent motion diffusion-weighted imaging in evaluating preoperative staging of esophageal squamous cell carcinoma : Evaluation of preoperative stage of primary tumour and prediction of lymph node metastases from esophageal ca2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  16. The MRI radiomics signature can predict the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.2024European radiology
  17. DDX5 promotes esophageal squamous cell carcinoma growth through sustaining VAV3 mRNA stability.2024Oncogene
  18. First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study.2024Signal transduction and targeted therapyFree full text
  19. Patterns and Influence of Lymph Nodal Metastases After Neoadjuvant Chemotherapy and Surgery for Thoracic Esophageal Squamous Cell Carcinoma.2023Annals of surgical oncology
  20. Prognostic significance of baseline peripheral blood lymphocyte subsets on second-line immunotherapy in advanced esophageal squamous cell carcinoma.2023Asian journal of surgery
  21. HA15 inhibits binding immunoglobulin protein and enhances the efficacy of radiation therapy in esophageal squamous cell carcinoma.2023Cancer scienceFree full text
  22. Stratification of lymph node metastasis improves diagnostic efficiency in thoracic esophageal squamous cell carcinoma.2023Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  23. Survival impact of the number of lymph nodes dissection in patients receiving neoadjuvant chemotherapy for esophageal squamous cell carcinoma.2023Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  24. A multicenter randomized, controlled clinical trial of adjuvant sintilimab for esophageal squamous cell carcinoma.2023Future oncology (London, England)RCT
  25. Initial experience with modified en bloc robot-assisted minimally invasive oesophagectomy for thoracic oesophageal squamous cell carcinoma.2023The international journal of medical robotics + computer assisted surgery : MRCAS
  26. Circular RNA hsa_circ_0000277 promotes tumor progression and DDP resistance in esophageal squamous cell carcinoma.2022BMC cancerFree full text
  27. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.2022BMC medicineFree full text
  28. Circ_0007624 suppresses the development of esophageal squamous cell carcinoma via targeting miR-224-5p/CPEB3 to inactivate the EGFR/PI3K/AKT signaling.2022Cellular signalling
  29. Quantitative RECIST derived from multiparametric MRI in evaluating response of esophageal squamous cell carcinoma to neoadjuvant therapy.2022European radiology
  30. Development and validation of MRI-based radiomics signatures models for prediction of disease-free survival and overall survival in patients with esophageal squamous cell carcinoma.2022European radiologyRCT
  31. Characterization of the Intra-tumoral B Cell Immunoglobulin Repertoire Is of Prognostic Value for Esophageal Squamous Cell Carcinoma.2022Frontiers in immunologyFree full text
  32. Targeting stearoyl-coa desaturase enhances radiation induced ferroptosis and immunogenic cell death in esophageal squamous cell carcinoma.2022OncoimmunologyFree full text
  33. Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma.2022Pathology oncology research : PORFree full text
  34. Comparative Clinical Efficacy of 'Concurrent Chemoradiotherapy (CCRT) and Anlotinib' Than CCRT in Patients with Locally Advanced ESCC.2022Technology in cancer research & treatmentFree full text
  35. Adjuvant Chemotherapy for Node-positive Esophageal Squamous Cell Carcinoma Improves Survival.2022The Annals of thoracic surgery
  36. Fusobacterium nucleatum predicts a high risk of metastasis for esophageal squamous cell carcinoma.2021BMC microbiologyFree full text
  37. Long non-coding RNA XIST promotes the progression of esophageal squamous cell carcinoma through sponging miR-129-5p and upregulating CCND1 expression.2021Cell cycle (Georgetown, Tex.)Free full text
  38. THAP9-AS1/miR-133b/SOX4 positive feedback loop facilitates the progression of esophageal squamous cell carcinoma.2021Cell death & diseaseFree full text
  39. The value of intravoxel incoherent motion diffusion-weighted imaging in predicting the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.2021European radiology
  40. The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.2021Frontiers in immunologyRCTFree full text
  41. lncRNA PART1, manipulated by transcriptional factor FOXP2, suppresses proliferation and invasion in ESCC by regulating the miR‑18a‑5p/SOX6 signaling axis.2021Oncology reportsFree full text
Chinese-language papers (not in the count)1
  1. [Application value of CT examination of lymph node short diameter in evaluating cardia-left gastric lymph node metastasis in thoracic esophageal squamous cell carcinoma].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status36
  1. Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant ImmunochemotherapyRecruitingNCT07629817Lead sponsorPhase 3Start 2026-06
  2. Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05495152Lead sponsorPhase 3Start 2022-08
  3. Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal CarcinomaRecruitingNCT04280822Lead sponsorPhase 3Start 2020-04
  4. Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)RecruitingNCT04138212Lead sponsorPhase 3Start 2019-10
  5. Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06888531Lead sponsorPhase 2Start 2025-03
  6. TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Status unknownNCT05013697Lead sponsorPhase 2Start 2021-09
  7. Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).Status unknownNCT04063683Lead sponsorPhase 2Start 2019-10
  8. Teripalimab Plus Chemotherapy in Local Advanced Esophageal CancerStatus unknownNCT03985670Lead sponsorPhase 2Start 2019-07
  9. Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell CarcinomaCompletedNCT02395705Lead sponsorPhase 3Start 2015-06
  10. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Study sitePhase 2Start 2026-07
  11. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  12. A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)RecruitingNCT07405151Study sitePhase 1/Phase 2Start 2026-03
  13. Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingNCT06780111Study sitePhase 1/Phase 2Start 2025-07
  14. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  15. A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Study sitePhase 1/Phase 2Start 2023-05
  16. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  17. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  18. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCStatus unknownNCT05221658Study sitePhase 2Start 2022-08
  19. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  20. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  21. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  22. JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard TherapyStatus unknownNCT05164848Study sitePhase 1Start 2021-12
  23. JAB-3068 Activity in Adult Patients With Advanced Solid TumorsCompletedNCT04721223Study sitePhase 1/Phase 2Start 2021-04
  24. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  25. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  26. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  27. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  28. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  29. Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03817567Study sitePhase 1/Phase 2Start 2018-07
  30. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  31. Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.CompletedNCT06190652Study siteStart 2018-10
  32. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  33. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  34. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
  35. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell CarcinomaStatus unknownNCT02409186Study sitePhase 3Start 2015-03
  36. Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 TrialStatus unknownNCT02319187Study sitePhase 3Start 2014-12
More papers found outside PubMed (not counted)42
  1. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. 349. PATHOLOGIC COMPLETE RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CANCER: DO DIVERSE NEOADJUVANT MODALITIES PREDICT PROGNOSTIC DIFFERENCES?2025Diseases of the Esophagusarticle
  3. 396. IRAE IN PHASE III STUDY ON NEOADJUVANT CHEMOTHERAPY VERSUS PERIOPERATIVE TORIPALIMAB PLUS NEOADJUVANT CHEMOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: HCHTOG19092025Diseases of the Esophagusarticle
  4. An interim analysis of phase III study on neoadjuvant chemotherapy versus perioperative toripalimab plus neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (H2025Journal of Clinical Oncologyconference-abstract
  5. CDK15 Promotes Esophageal Squamous Cell Carcinoma Progression by Phosphorylating HK2 and Regulating Glycolysis2025International Journal of Radiation Oncology*Biology*Physicsconference-abstract
  6. Efficacy and safety results of a multi-center phase II study of utidelone injection in combination with PD-1 inhibitor and chemotherapy for the first-line treatment of advanced gastric and esophagus cancers.2025Journal of Clinical Oncologyconference-abstract
  7. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncologyconference-abstract
  8. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyconference-abstract
  9. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncologyarticle
  10. A Phase II Clinical Trial of Radiotherapy Combined with Anlotinib in Locoregional Recurrent Esophageal Squamous Cell Carcinoma after Radical Surgery2024International Journal of Radiation Oncology*Biology*Physicsarticle
  11. A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  12. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Researchconference-abstract
  13. Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncologyconference-abstract
  14. Development of a new EGFR-VHH-CAR T-cell therapy for treatment of esophageal squamous cell carcinoma2024Research Squarepreprint
  15. First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.2024Journal of Clinical Oncologyconference-abstract
  16. PDIA6 promotes the progression of ESCC via AKT1/mTOR signal pathway by forming disulfide-dependent TRAF42024Research Squarepreprint
  17. The Prognostic Significance of Tertiary Lymphoid Structure Assessment with Hematoxylin and Eosin Sections in Esophageal Squamous Cell Carcinoma2024Research Squarepreprint
  18. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical t2024Journal of Clinical Oncologyconference-abstract
  19. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncologyarticle
  20. 95P A single-arm, multicenter phase II trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)2023Immuno-Oncology Technologyarticle
  21. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncologyconference-abstract
  22. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  23. TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase Ⅱ trial.2023Journal of Clinical Oncologyconference-abstract
  24. 164P TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter phase Ⅱ trial2022Immuno-Oncology Technologyarticle
  25. 476. SONIC HEDGEHOG POSITIVE EXPRESSION IS ASSOCIATED WITH PROGNOSIS AND THE RESPONSE OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA TO NEOADJUVANT CHEMOTHERAPY2022Diseases of the Esophagusarticle
  26. Effect of postoperative adjuvant chemotherapy on esophageal squamous cell carcinoma patients with lymphovascular invasion and without lymph node metastasis2022Research Squarepreprint
  27. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  28. Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncologyconference-abstract
  29. Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncologyconference-abstract
  30. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2022Journal of Clinical Oncologyconference-abstract
  31. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  32. 285 RIGHT COMPARED WITH LEFT THORACIC APPROACH ESOPHAGECTOMY FOR PATIENTS WITH MIDDLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2021Diseases of the Esophagusarticle
  33. 624 A PHASE III STUDY ON NEOADJUVANT TORIPALIMAB PLUS CHEMOTHERAPY VERSUS NEOADJUVANT CHEMOTHERAPY FOR LOCALLY RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2021Diseases of the Esophagusarticle
  34. Analysis of Key Pathways, Genes and Immune Cell Infiltration in Metastatic Esophageal Squamous Cell Carcinoma Based on Bioinformatics2021Research Squarepreprint
  35. CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  36. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncologyconference-abstract
  37. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  38. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  39. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract
  40. The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study.2021Journal of Clinical Oncologyconference-abstract
  41. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncologyconference-abstract
  42. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 34 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
34
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
10
led by another institution
Papers led per year
2021: 6620212022: 7720222023: 6620232024: 7720242025: 662025

3 hospitals in Zhengzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06478927

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  2. Recruiting
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07479485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou

  3. Recruiting
    HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06737913

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Zhengzhou

  4. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07239245

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesBeijing, Shenyang, Zhengzhou

  6. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  7. Recruiting
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07391839

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou

  8. Recruiting
    A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06371157

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Hangzhou, Nanjing, Zhengzhou

  9. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  10. Recruiting
    A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-04
    Registry
    NCT06508307

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  11. Not yet recruiting
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06779461

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)Immunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineRadiation oncologyMedical oncology
Papers it led34
  1. Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. SAE1 emerges as a pan-cancer driver and key regulator of HCC metastasis.2026Journal of advanced researchFree full text
  3. Adjuvant Transarterial Chemoembolization in Resected Macrotrabecular-massive Hepatocellular Carcinoma (ATAC-MACRO): A Multicenter Real-world Retrospective Study.2025Academic radiology
  4. CircMFN2/miR-361-3p/ELK1 feedback loop promotes glutaminolysis and the progression of hepatocellular carcinoma.2025Cancer letters
  5. Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study.2025Frontiers in immunologyFree full text
  6. How different body compositions affect the prognosis of HCC undergoing immunotherapy: the paradoxical phenomenon of BMI.2025La Radiologia medica
  7. Glutamate promotes CCL2 expression to recruit tumor-associated macrophages by restraining EZH2-mediated histone methylation in hepatocellular carcinoma.2025OncoimmunologyFree full text
  8. Analysis of the efficacy of splenic artery superselective embolization in cirrhosis with hepatocellular carcinoma.2025PloS oneFree full text
  9. Relationship between TIGIT expression on T cells and the prognosis of patients with hepatocellular carcinoma.2024BMC cancerFree full text
  10. UCHL5 promotes hepatocellular carcinoma progression by promoting glycolysis through activating Wnt/β-catenin pathway.2024BMC cancerFree full text
  11. Laparoscopic liver resection versus radiofrequency ablation for caudate lobe solitary hepatocellular carcinoma: A propensity score matching study.2024Cancer medicine
  12. Histamine-related genes participate in the establishment of an immunosuppressive microenvironment and impact the immunotherapy response in hepatocellular carcinoma.2024Clinical and experimental medicineFree full text
  13. Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning.2024Frontiers in immunologyFree full text
  14. Pan-cancer analysis of DCTN2 and its tumour-promoting role in HCC by modulating the AKT pathway.2024Journal of cellular and molecular medicineFree full text
  15. CD69+ Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma.2024Molecular immunology
  16. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.2023Cancer immunology, immunotherapy : CIIFree full text
  17. Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma.2023Clinical and experimental medicine
  18. Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.2023Clinical and translational gastroenterologyFree full text
  19. The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy.2023Hepatology international
  20. Correlation of Serum Chemokine Ligand 14 with Barcelona Clinic Liver Cancer Stage, Lymphocyte Profile, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.2023Journal of vascular and interventional radiology : JVIR
  21. Nuclear translocation of YAP drives BMI-associated hepatocarcinogenesis in hepatitis B virus infection.2023Liver international : official journal of the International Association for the Study of the Liver
  22. Radiofrequency ablation combined with transarterial chemoembolization in treatment of hepatocellular carcinoma adjacent to the second hepatic hilus.2022Abdominal radiology (New York)Free full text
  23. HBX suppresses PTEN to promote the malignant progression of hepatocellular carcinoma through mi-R155 activation.2022Annals of hepatology
  24. Risk of Liver Cirrhosis in HBV/HCV-Infected Individuals with First-Degree Relatives Who Have Liver Cancer: Development and Validation of a Simple Model.2022Cancer prevention research (Philadelphia, Pa.)
  25. Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  26. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  27. MiR-122 radiosensitize hepatocellular carcinoma cells by suppressing cyclin G1.2022International journal of radiation biology
  28. Useful genes for predicting the efficacy of transarterial chemoembolization in hepatocellular carcinoma.2022Journal of cancer research and therapeutics
  29. Gastroesophageal junction cancer with hepatic metastasis: Effective Treatment using microsphere embolization combined with transarterial infusion chemotherapy.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the LiverRCT
  30. Clinical observation of local intervention combined with camrelizumab and apatinib in the treatment of metastatic soft-tissue sarcoma.2021Journal of cancer research and therapeutics
  31. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.2021Journal of cellular physiology
  32. An Integrated Transcriptomics and Proteomics Analysis Implicates lncRNA MALAT1 in the Regulation of Lipid Metabolism.2021Molecular & cellular proteomics : MCPFree full text
  33. Silencing the Expression of Cyclin G1 Enhances the Radiosensitivity of Hepatocellular Carcinoma In Vitro and In Vivo by Inducing Apoptosis.2021Radiation research
  34. DEAD-box Helicase 27 Promotes Hepatocellular Carcinoma Progression Through ERK Signaling.2021Technology in cancer research & treatmentFree full text
Chinese-language papers (not in the count)4
  1. [Advances in the application of selective internal radiation therapy in the treatment of hepatocellular carcinoma].2025Zhonghua nei ke za zhi
  2. [Current status, challenges and strategy of combination treatment of local interventional therapy and immunotherapy for primary hepatocellular carcinoma].2022Zhonghua nei ke za zhi
  3. [Curative effect analysis of ultrasound-guided percutaneous radiofrequency ablation for caudate lobe hepatocellular carcinoma].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  4. [Correlation analysis of Ki67, Ck19 with clinicopathological features and apparent diffusion coefficient value of hepatocellular carcinoma].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status33
  1. Backline Treatment of Advanced Hepatocellular Carcinoma With PalbociclibRecruitingNCT06478927Lead sponsorN/AStart 2024-01
  2. Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot StudyStatus unknownNCT06685354Lead sponsorPhase 2Start 2024-11
  3. Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular CarcinomaStatus unknownNCT05024539Lead (inferred)Start 2021-06
  4. MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)RecruitingNCT07479485Study sitePhase 1/Phase 2Start 2026-04
  5. Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular CarcinamoRecruitingNCT07239245Study sitePhase 2Start 2025-11
  6. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.RecruitingNCT07391839Study sitePhase 1Start 2025-08
  7. HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular CarcinomaRecruitingNCT06737913Study sitePhase 2Start 2025-01
  8. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  9. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  10. A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular CarcinomaNot yet recruitingNCT06779461Study sitePhase 3Start 2025-01
  11. A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular CarcinomaRecruitingNCT06371157Study sitePhase 3Start 2024-08
  12. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  13. A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid TumorsRecruitingNCT06508307Study sitePhase 1Start 2023-04
  14. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  15. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedNCT06487559Study sitePhase 1Start 2024-09
  16. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT06310590Study sitePhase 1Start 2023-08
  17. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCCWithdrawnNCT05212922Study sitePhase 2Start 2023-06
  18. A Phase II Study of AK104 Plus Lenvatinib and TACE in HCCActive, not recruitingNCT05319431Study sitePhase 2Start 2022-06
  19. PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaCompletedNCT05864105Study sitePhase 2Start 2022-04
  20. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  21. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Study sitePhase 2Start 2021-01
  22. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  23. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  24. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver CancerTerminatedNCT04520906Study siteN/AStart 2020-12
  25. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  26. A Phase I/II Study of AST-3424 in Subjects With Advanced Solid TumorsActive, not recruitingNCT06239155Study sitePhase 1/Phase 2Start 2019-09
  27. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  28. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local AblationStatus unknownNCT03356236Study siteStart 2018-04
  29. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  30. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  31. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Study sitePhase 2Start 2017-05
  32. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular CarcinomaCompletedNCT03113955Study siteN/AStart 2017-10
  33. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaCompletedNCT02508467Study sitePhase 1Start 2015-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 76 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.8%.

Papers led
76
2021–2025
Trials led
17
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
16
led by another institution
Papers led per year
2021: 5520212022: 121220222023: 202020232024: 191920242025: 20202025

4 hospitals in Zhengzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 20

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-02
    Registry
    NCT07334431

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  2. Recruiting
    A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06774222

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  3. Recruiting
    Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2021-06
    Registry
    NCT04891016

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  4. Not yet recruiting
    Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07610629

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  5. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  6. Recruiting
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06901531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  7. Recruiting
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07066657

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou

  8. Recruiting
    An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Registry
    NCT07371663

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Zhengzhou

  9. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  10. Recruiting
    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06469944

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Urumqi, Xiamen, Zhengzhou

  11. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  12. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  13. Recruiting
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05722275

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou

  14. Recruiting
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2023-04
    Registry
    NCT05918094

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChengdu, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou

  15. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  16. Recruiting
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06155383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou

  17. Recruiting
    A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-04
    Registry
    NCT06508307

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  18. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  19. Recruiting
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    Phase
    Phase 1
    Started
    2022-06
    Registry
    NCT05365581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou

  20. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseChemotherapy & combined treatmentImaging & AI
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineRadiation oncology
Papers it led76
  1. Advanced diffusion-weighted MRI models for preoperative prediction of lymph node metastasis in resectable gastric cancer.2025Abdominal radiology (New York)
  2. A machine learning approach to risk-stratification of gastric cancer based on tumour-infiltrating immune cell profiles.2025Annals of medicineFree full text
  3. Efficacy and safety of XELOX combined with neoadjuvant radiotherapy versus neoadjuvant chemotherapy in locally advanced gastric cancer.2025BMC cancerFree full text
  4. Potential predictive value of CD8A and PGF protein expression in gastric cancer patients treated with neoadjuvant immunotherapy.2025BMC cancerFree full text
  5. Comparison of 2D and 3D measured iodine concentration of gastric adenocarcinoma on spectral-CT and their relationship with perineural invasion.2025BMC medical imagingFree full text
  6. Single-arm, open-label, multicentre phase 1b/2 study to evaluate the safety and efficacy of fruquintinib combined with sintilimab and CAPEOX as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (FUNCTIO2025BMJ openFree full text
  7. Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study.2025Cell reports. MedicineFree full text
  8. Dual-energy CT radiomics for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer: A dual-vendor validation study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  9. Sequential dual-energy CT for longitudinal assessment of pathologic response to neoadjuvant immuno-chemotherapy in locally advanced gastric cancer.2025European radiology
  10. Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.2025Frontiers in immunologyFree full text
  11. Integrative multi-omics analysis of gastric cancer evolution from precancerous lesions to metastasis identifies a deep learning-based prognostic model.2025Frontiers in immunologyFree full text
  12. High expression of CXCL13 predicts a favorable response to immunotherapy by upregulating CXCR5+CD8+ T-cell infiltration in gastric cancer.2025Frontiers in immunologyFree full text
  13. Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis.2025Frontiers in immunologyFree full text
  14. Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  15. Gastric Carcinoma Patients with Advanced Pathological Lymph Node Stage Benefit from Postoperative Radiotherapy: A Retrospective Analysis.2025Journal of gastrointestinal cancer
  16. Efficacy and prognostic factors of PD-1 inhibitors combined with apatinib in advanced diffuse gastric cancer.2025Neoplasma
  17. The downregulation of ubiquitin-specific peptidase 2 indicates a poor prognosis and promotes the progression of gastric cancer through focal adhesion and ECM pathway signaling.2025Scientific reportsFree full text
  18. Impact of Tregs on tumor regression in locally advanced G/GEJ cancer patients undergoing neoadjuvant chemoimmunotherapy.2025Scientific reportsFree full text
  19. A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer.2025Scientific reportsFree full text
  20. Overexpression of CAD in stomach adenocarcinoma tissues and its clinical significance.2025Seminars in oncology
  21. Preoperative Risk Stratification for Gastric Cancer: The Establishment of Dual-Energy CT-Based Radiomics Using Prospective Datasets at Two Centers.2024Academic radiology
  22. Identification of neutrophil extracellular trap-driven gastric cancer heterogeneity and C5AR1 as a therapeutic target.2024Acta biochimica et biophysica SinicaFree full text
  23. A modified left-sided approach of laparoscopic radical distal gastrectomy for improving outcomes: A video vignette.2024Asian journal of surgery
  24. Enhancing exposure and safety in laparoscopic gastrectomy: The anterior approach for duodenum-first procedure-A video vignette.2024Asian journal of surgery
  25. Integrated analysis of the role of PR/SET domain 14 in gastric cancer.2024BMC cancerFree full text
  26. Development and validation of a deep learning model for predicting postoperative survival of patients with gastric cancer.2024BMC public healthFree full text
  27. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.2024Clinical and translational medicineFree full text
  28. The value of intravoxel incoherent motion diffusion-weighted imaging in predicting perineural invasion for resectable gastric cancer: a prospective study.2024Clinical radiology
  29. Downregulation of HIGD1B induces mitochondria-mediated apoptosis in gastric cancer cells by inactivating Akt and ERK pathways.2024Drug development research
  30. Discovery of novel coumarin-based derivatives as inhibitors of tubulin polymerization targeting the colchicine binding site with potent anti-gastric cancer activities.2024European journal of medicinal chemistry
  31. Predicting pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer: The establishment of a spectral CT-based nomogram from prospective datasets.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  32. Spectral CT vs. diffusion-weighted imaging for the quantitative prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer.2024European radiology
  33. A novel platelets-related gene signature for predicting prognosis, immune features and drug sensitivity in gastric cancer.2024Frontiers in immunologyFree full text
  34. HER2+ advanced gastric cancer: Current state and opportunities (Review).2024International journal of oncologyFree full text
  35. The SIX2/PFN2 feedback loop promotes the stemness of gastric cancer cells.2024Journal of translational medicineFree full text
  36. A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer.2024Med (New York, N.Y.)RCT
  37. Development and validation of a nomogram for predicting survival in gastric signet ring cell carcinoma patients treated with radiotherapy.2024Scientific reportsFree full text
  38. Oxaliplatin-induced upregulation of exosomal miR-424-3p derived from human bone marrow mesenchymal stem cells attenuates progression of gastric cancer cells.2024Scientific reportsFree full text
  39. Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer.2024Technology in cancer research & treatmentFree full text
  40. Application of intravoxel incoherent motion diffusion-weighted imaging for preoperative knowledge of lymphovascular invasion in gastric cancer: a prospective study.2023Abdominal radiology (New York)
  41. lncRNA ELFN1-AS1 upregulates TRIM29 by suppressing miR-211-3p to promote gastric cancer progression.2023Acta biochimica et biophysica SinicaFree full text
  42. Primary gastric melanoma: A case report.2023Asian journal of surgery
  43. Laparoscopic total gastrectomy with partial duodenectomy and cholecystectomy for locally advanced gastric cancer(with video).2023Asian journal of surgery
  44. A male with synchronous multiple primary malignant tumors including gastric, colon and prostate cancer.2023Asian journal of surgery
  45. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.2023BMC cancerFree full text
  46. NREP is a Diagnostic and Prognostic Biomarker, and Promotes Gastric Cancer Cell Proliferation and Angiogenesis.2023Biochemical genetics
  47. Increased lncRNA AFAP1-AS1 expression predicts poor prognosis in gastric cancer: Evidence from published studies and followed up verification.2023Cancer medicineFree full text
  48. Multiparametric MRI-based radiomics nomogram for early prediction of pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer.2023European radiology
  49. Spectral CT-based nomogram for preoperative prediction of perineural invasion in locally advanced gastric cancer: a prospective study.2023European radiology
  50. Genetic risk and gastric cancer: polygenic risk scores in population-based case-control study.2023Expert review of molecular diagnostics
  51. Knockdown of kinesin family member 2C restricts cell proliferation and induces cell cycle arrest in gastric cancer.2023Histology and histopathology
  52. Fusobacterium nucleatum Promotes Megakaryocyte Maturation in Patients with Gastric Cancer via Inducing the Production of Extracellular Vesicles Containing 14-3-3ε.2023Infection and immunityFree full text
  53. Long noncoding RNA ZEB1-AS1 attenuates ferroptosis of gastric cancer cells through modulating miR-429/BGN axis.2023Journal of biochemical and molecular toxicology
  54. A Retrospective Cohort Study Examining the Effects of Anti-PD-1 Antibody in Combination with Apatinib in Patients Previously Treated for Her2-Negative Advanced Gastric/Gastroesophageal Junction Cancer.2023Journal of clinical pharmacology
  55. Increased Expression of POSTN Predicts Poor Prognosis: a Potential Therapeutic Target for Gastric Cancer.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  56. Diagnostic and Prognostic Value of CPZ in Patients with Gastric Cancer by Integrated Analysis.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  57. Comparison of MRI and CT-Based Radiomics and Their Combination for Early Identification of Pathological Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.2023Journal of magnetic resonance imaging : JMRIRCT
  58. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.2023Technology in cancer research & treatmentFree full text
  59. Is single tract jejunal interposition better than double tract reconstruction after proximal gastrectomy?2023Updates in surgery
  60. Dynamic contrast-enhanced and diffusion-weighted MR imaging in early prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer.2022Abdominal radiology (New York)
  61. Machine learning analysis for the noninvasive prediction of lymphovascular invasion in gastric cancer using PET/CT and enhanced CT-based radiomics and clinical variables.2022Abdominal radiology (New York)RCT
  62. A novel method for liver retraction in laparoscopic gastric cancer surgery: A video vignette.2022Asian journal of surgery
  63. "Straight-line modular" operation mode of upper pancreatic lymph-node dissection in laparoscopic radical resection of proximal gastric cancer (with Video).2022Asian journal of surgery
  64. Application of the sandwich technique in porta-hepatis lymph-node dissection: A video vignette.2022Asian journal of surgery
  65. "Lateral approach" for infra-pyloric lymphadenectomy in laparoscopic radical gastrectomy: A video vignette.2022Asian journal of surgery
  66. CD142 plays a key role in the carcinogenesis of gastric adenocarcinoma by inhibiting BCL2-dependent autophagy.2022Biochemistry and cell biology = Biochimie et biologie cellulaire
  67. Characterization of gastric cancer stem-like molecular features, immune and pharmacogenomic landscapes.2022Briefings in bioinformatics
  68. Key Targets and Molecular Mechanisms of Active Volatile Components of Rabdosia rubescens in Gastric Cancer Cells.2022Current computer-aided drug designFree full text
  69. A high interferon gamma signature of CD8+ T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer.2022Frontiers in immunologyFree full text
  70. A commentary on "Gastrectomy with omentum preservation versus gastrectomy with omentectomy for locally advanced gastric cancer: A systematic review and meta-analysis" (Int J Surg 2021;96:106176).2022International journal of surgery (London, England)
  71. Prognostic and Predictive Model of the Log Odds of the Negative Lymph Node/T Stage Ratio in Resectable Gastric Adenocarcinoma Patients.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractRCT
  72. Identification and epidemiological evaluation of gastric cancer risk factors: based on a field synopsis and meta-analysis in Chinese population.2021AgingFree full text
  73. "Sandwich" infrapyloric lymphadenectomy in laparoscopic radical gastrectomy: A video vignette.2021Asian journal of surgery
  74. Discovering the mechanism and involvement of the methylation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and its special locus region in gastric cancer.2021BioengineeredFree full text
  75. Polygenic Risk Scores for Prediction of Gastric Cancer Based on Bioinformatics Screening and Validation of Functional lncRNA SNPs.2021Clinical and translational gastroenterologyFree full text
  76. A risk signature with inflammatory and immune cells infiltration predicts survival and efficiency of chemotherapy in gastric cancer.2021International immunopharmacology
Chinese-language papers (not in the count)5
  1. [Clinical analysis of immunotherapy rechallenge in advanced gastric cancer].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Study on the dynamic changes of peripheral platelet-to-lymphocyte ratio in the prognosis of neoadjuvant chemotherapy patients with gastric cancer].2022Zhonghua yi xue za zhi
  3. [Changing trend of incidence and mortality of stomach cancer during 2010-2016 in Henan Province, China].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [Quality assessment of guidelines on upper gastrointestinal cancer screening].2021Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  5. [The value of spleen density in predicting prognosis of patients with gastric cancer after curative gastrectomy].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status67
  1. Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction CancerNot yet recruitingNCT07610629Lead sponsorPhase 2Start 2026-05
  2. Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric CancerRecruitingNCT07334431Lead sponsorPhase 1/Phase 2Start 2024-02
  3. A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRGRecruitingNCT06774222Lead sponsorPhase 2Start 2023-09
  4. Toripalimab Plus FLOT in Locally Advanced Gastric CancerRecruitingNCT04891016Lead sponsorPhase 2Start 2021-06
  5. Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 OverexpressionStatus unknownNCT06227325Lead sponsorPhase 2Start 2024-02
  6. RC48 Plus AK105 and Cisplatin in Advanced Gastric CancerStatus unknownNCT05313906Lead sponsorPhase 2Start 2022-05
  7. Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric CancerActive, not recruitingNCT05177068Lead sponsorPhase 2Start 2022-05
  8. Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric AdenocarcinomaStatus unknownNCT04948125Lead sponsorPhase 2Start 2021-04
  9. TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT04891900Lead sponsorN/AStart 2021-05
  10. Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric CancerStatus unknownNCT04675866Lead sponsorN/AStart 2020-08
  11. SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT03950271Lead sponsorPhase 2Start 2020-01
  12. Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional AdenocarcinomaStatus unknownNCT03939962Lead sponsorPhase 2Start 2019-07
  13. Study of CT and MR in the Gastric CancerStatus unknownNCT04028375Lead sponsorStart 2019-09
  14. A Real World Study of Apatinib in Treatment of Patients With Gastric CarcinomaStatus unknownNCT03735511Lead sponsorStart 2018-11
  15. The Real World Study of Apatinib for Gastric Cancer Treatment in Henan ProvinceStatus unknownNCT03478943Lead sponsorStart 2016-01
  16. A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric CancerStatus unknownNCT04351867Lead (inferred)Phase 3Start 2020-09
  17. Irinotecan Plus Thalidomide in Second Line Advanced Gastric CancerStatus unknownNCT02401971Lead (inferred)Phase 4Start 2014-08
  18. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Study sitePhase 3Start 2025-05
  19. A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsRecruitingNCT07066657Study sitePhase 1Start 2025-07
  20. An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsRecruitingNCT07371663Study sitePhase 1/Phase 2Start 2025-12
  21. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  22. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  23. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  24. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingNCT06324357Study sitePhase 1/Phase 2Start 2024-06
  25. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingNCT06469944Study sitePhase 1/Phase 2Start 2024-09
  26. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Study sitePhase 2Start 2023-11
  27. A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid TumorsRecruitingNCT06508307Study sitePhase 1Start 2023-04
  28. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT05918094Study sitePhase 3Start 2023-04
  29. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  30. Prediction of Peritoneal Metastasis for Gastric Cancer Based on RadiomicsRecruitingNCT05722275Study siteStart 2023-01
  31. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  32. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Study sitePhase 1Start 2022-06
  33. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Study sitePhase 1Start 2021-06
  34. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  35. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.Active, not recruitingNCT06116136Study sitePhase 1/Phase 2Start 2024-08
  36. EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung CancerWithdrawnNCT05411679Study sitePhase 2Start 2023-04
  37. Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East AsiaCompletedNCT05606094Study siteStart 2023-03
  38. Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid TumorsCompletedNCT05538195Study sitePhase 1/Phase 2Start 2022-06
  39. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  40. To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT05253053Study sitePhase 1/Phase 2Start 2022-04
  41. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  42. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  43. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  44. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  45. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric CarcinomaTerminatedNCT04718402Study sitePhase 1Start 2021-03
  46. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  47. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Study sitePhase 2Start 2020-05
  48. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  49. IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ AdenocarcinomaCompletedNCT05327231Study sitePhase 1Start 2020-07
  50. Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal MetastasisStatus unknownNCT04222114Study sitePhase 3Start 2020-10
  51. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  52. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid TumorsCompletedNCT04400383Study sitePhase 1Start 2020-06
  53. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  54. Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ CancerWithdrawnNCT04348643Study sitePhase 1/Phase 2Start 2020-02
  55. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Study sitePhase 1Start 2020-02
  56. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  57. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Study sitePhase 2/Phase 3Start 2019-09
  58. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  59. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  60. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  61. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  62. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  63. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  64. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05
  65. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  66. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  67. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Zhengzhou for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 19 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
19
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 7720212022: 2220222023: 3320232024: 2220242025: 442025

16 hospitals in Zhengzhou for osteosarcoma742 hospitals in China for osteosarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05830123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led19
  1. Cancer-associated fibroblast exosomal miR-214-3p regulated by hnRNPA2B1 promotes cisplatin resistance by inhibiting ferroptosis.2026International journal of surgery (London, England)
  2. Dual-Functional Interface Engineering of Mesoporous Bioactive Glass via Polydopamine Chelation for 3D-Printed Scaffolds with Synergistic Photothermal Therapy and Enhanced Osteogenesis.2025ACS applied materials & interfaces
  3. Rab27b-mediated CAFs derived exosomal miR-22-3p suppresses ferroptosis and promotes cisplatin resistance in osteosarcoma.2025Cellular signalling
  4. Rab27a+CAF exosomal miR-9-5p promotes osteosarcoma progression via CREBRF/MAPK signaling pathway.2025Cellular signalling
  5. Exosomal miR-20a-5p derived from cisplatin-resistant osteosarcoma cells promotes chemoresistance via Inhibition of ferroptosis through targeting RUNX3.2025Scientific reports
  6. Circ_UBAP2 exacerbates proliferation and metastasis of OS via targeting miR-665/miR-370-3p/HMGA1 axis.2024Environmental toxicology
  7. Inactivation and replantation of the knee joint: an infeasible surgical method.2024World journal of surgical oncology
  8. The promising roles of exosomal microRNAs in osteosarcoma: A new insight into the clinical therapy.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. LncRNA STK4 antisense RNA 1 (STK4-AS1) promoted osteosarcoma by inhibiting p53 expression.2023Cancer biomarkers : section A of Disease markers
  10. COPS3 inhibition promotes cell proliferation blockage and anoikis via regulating PFKFB3 in osteosarcoma cancer cells.2023European journal of pharmacology
  11. Circular RNA circ_UBAP2 facilitates the progression of osteosarcoma by regulating microRNA miR-637/high-mobility group box (HMGB) 2 axis.2022Bioengineered
  12. Construction and validation of a novel gene signature for predicting the prognosis of osteosarcoma.2022Scientific reports
  13. Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis.2021Anti-cancer drugs
  14. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.2021Cancer medicine
  15. TNK2-AS1 upregulated by YY1 boosts the course of osteosarcoma through targeting miR-4319/WDR1.2021Cancer science
  16. The LINC01410/miR-122-5p/NDRG3 axis is involved in the proliferation and migration of osteosarcoma cells.2021IUBMB life
  17. circUBAP2 regulates osteosarcoma progression via the miR‑204‑3p/HMGA2 axis.2021International journal of oncology
  18. Long noncoding RNA LINC01410 promotes tumorigenesis of osteosarcoma cells via miR-497-5p/HMGA2 axis.2021Journal of biochemical and molecular toxicology
  19. lncRNA‑CASC15 promotes osteosarcoma proliferation and metastasis by regulating epithelial‑mesenchymal transition via the Wnt/β‑catenin signaling pathway.2021Oncology reports
Chinese-language papers (not in the count)2
  1. [Effectiveness evaluation of three-dimensional printed titanium-alloy prosthesis reconstruction after distal tibia tumor segment resection].2022Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  2. [Role of CT and MRI image fusion and computer assisted simulation technique in guiding type Ⅲ and Ⅳ primary pelvic sarcoma surgeries].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
Earlier papers (2016–2020)7
  1. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.2020Investigational new drugs
  2. MicroRNA-761 suppresses tumor progression in osteosarcoma via negatively regulating ALDH1B1.2020Life sciences
  3. Experimental Study of Somatic Variants of Osteosarcoma by Whole-Exome Sequencing.2020Medical science monitor : international medical journal of experimental and clinical research
  4. Mid- to long-term effects of two different biological reconstruction techniques for the treatment of humerus osteosarcoma involving caput humeri.2020World journal of surgical oncology
  5. Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study.2019Medicine
  6. Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo.2018Cancer biomarkers : section A of Disease markers
  7. Correlations Between Hector Battifora Mesothelial-1 (HBME-1) Expression and Clinical Pathological Characteristics and Prognosis of Osteosarcoma Patients.2017Medical science monitor : international medical journal of experimental and clinical research
All its trials on ClinicalTrials.gov, any status2
  1. Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.Status unknownNCT03163381Lead sponsorPhase 2Start 2017-04
  2. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other SarcomasRecruitingNCT05830123Study sitePhase 2Start 2023-06

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

5 hospitals in Zhengzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

  2. Recruiting
    A Study of HQP1351 in Patients With GIST or Other Solid Tumors
    Phase
    Phase 1
    Started
    2018-07
    Registry
    NCT03594422

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led1
  1. A case of gene mutation responsible for GIST drug resistance.2023Asian journal of surgery
All its trials on ClinicalTrials.gov, any status2
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Study sitePhase 1Start 2018-07

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

7 hospitals in Zhengzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led1
  1. Dyngo-4a Induces Neuroblastoma Cell Differentiation Through The AKT and ERK1/2 Pathway.2023CNS & neurological disorders drug targets

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Zhengzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Effectiveness evaluation of three-dimensional printed titanium-alloy prosthesis reconstruction after distal tibia tumor segment resection].2022Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's SarcomaCompletedNCT05046314Study sitePhase 2Start 2024-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 18 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.1%.

Papers led
18
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
17
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 4420232024: 2220242025: 662025

4 hospitals in Zhengzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 17

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07454187

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Suzhou, Xi'an, Zhengzhou

  2. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  3. Recruiting
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07663253

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou

  4. Recruiting
    A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07294625

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 4 listed hospitals as study sitesNanjing, Shanghai, Xi'an, Xuzhou, Zhengzhou

  5. Recruiting
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06375044

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou

  6. Recruiting
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06508983

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou

  7. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  8. Recruiting
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07028970

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou

  9. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  10. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  11. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  12. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  13. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  14. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  15. Not yet recruiting
    A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07399444

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesNanchang, Tianjin, Wuhan, Xuzhou, Zhengzhou

  16. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

  17. Not yet recruiting
    LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2024-07
    Registry
    NCT06472479

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesHefei, Nanjing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantRelapse & resistanceDrug combinations
Departments in papersMedical oncology
Papers it led18
  1. Tandem autologous hematopoietic stem cell transplantation in multiple myeloma: A historical perspective and current challenges.2025Annals of hematologyFree full text
  2. Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies.2025British journal of haematologyFree full text
  3. Therapeutic options for extramedullary involvement in multiple myeloma.2025Clinical and experimental medicineFree full text
  4. Epirubicin Induces Cell Cycle Arrest in Multiple Myeloma Cells by Downregulating CDC20 Expression.2025Frontiers in bioscience (Landmark edition)
  5. Clinical characteristics and risk factors of infection in initially treated patients with multiple myeloma during the induction period.2025Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  6. Impact of type 2 and steroid-Induced diabetes mellitus on prognosis in patients with multiple myeloma.2025World journal of surgical oncologyFree full text
  7. Identification of potential immune-related mechanisms related to the development of multiple myeloma.2024Chinese medical journalFree full text
  8. Research Progress on Ferroptosis in Multiple Myeloma.2024Current treatment options in oncologyFree full text
  9. Hsa_circ_0111738 Inhibits Tumor Progression and Angiogenesis in Multiple Myeloma by Sponging miR-1233-3p to Regulate HIF-1 Signaling Pathway.2023Archives of medical research
  10. Efficacy and safety of bortezomib plus dexamethasone in patients with refractory primary immune thrombocytopenia: A single-center study.2023Asian journal of surgery
  11. Clonal haematopoiesis of indeterminate potential predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.2023British journal of haematology
  12. Mitochondrial dysfunction and drug targets in multiple myeloma.2023Journal of cancer research and clinical oncologyFree full text
  13. Experimental study on thioredoxin redox inhibitor 1-methylpropyl 2-imidazolyl disulfide promoting apoptosis of multiple myeloma cells in vitro and in vivo.2022European review for medical and pharmacological sciences
  14. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.2022Frontiers in immunologyFree full text
  15. Glutathione combined with mecobalamin in the treatment of chemotherapy-induced peripheral neuropathy in multiple myeloma: a retrospective clinical study.2021Annals of palliative medicine
  16. Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma.2021Biochemical and biophysical research communications
  17. miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition.2021International journal of cancerFree full text
  18. Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma.2021LeukemiaFree full text
Chinese-language papers (not in the count)4
  1. [Research Progress of Clonal Hematopoiesis of Indeterminate Potential in Multiple Myeloma --Review].2022Zhongguo shi yan xue ye xue za zhi
  2. [Expression of miR-17-5p in the plasma of patients with multiple myeloma and its role in tumorigenesis and development].2022Zhonghua yi xue za zhi
  3. [PX-12 Promoting Apoptosis of Multiple Myeloma Cell Line H929 Induced by Bortezomib].2021Zhongguo shi yan xue ye xue za zhi
  4. [Treatment of two cases of extramedullary infiltration multiple myeloma with BCMA CAR-T cells].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status48
  1. BCMA-CAR-T in Relapsed/Refractory Multiple MyelomaStatus unknownNCT03664661Lead sponsorPhase 1Start 2018-04
  2. Study of BCMA CAR-T in Multiple MyelomaStatus unknownNCT03322735Lead sponsorPhase 1/Phase 2Start 2017-12
  3. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  4. To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07454187Study sitePhase 1/Phase 2Start 2026-04
  5. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  6. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma(LB2505-0001)Not yet recruitingNCT07399444Study siteEarly phase 1Start 2026-01
  7. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  8. A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT07294625Study siteEarly phase 1Start 2025-12
  9. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Study sitePhase 1Start 2024-05
  10. Long-term Follow-up Registry Study of Equecabtagene Autoleucel InjectionRecruitingNCT07028970Study siteStart 2024-12
  11. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingNCT06508983Study sitePhase 3Start 2024-06
  12. A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Study sitePhase 1Start 2024-06
  13. LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06472479Study siteN/AStart 2024-07
  14. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  15. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  16. Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Study sitePhase 2Start 2022-04
  17. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  18. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  19. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  20. Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple MyelomaActive, not recruitingNCT06924424Study siteN/AStart 2025-03
  21. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  22. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  23. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  24. Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05719701Study sitePhase 1/Phase 2Start 2023-03
  25. A Clinical Trial of TQB2934 for Injection in Multiple Myeloma SubjectsStatus unknownNCT05646758Study sitePhase 1Start 2023-03
  26. Clinical Study of the Safety and Efficacy of BCMA CAR-NKStatus unknownNCT05652530Study siteEarly phase 1Start 2022-11
  27. Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple MyelomaActive, not recruitingNCT05363800Study sitePhase 1Start 2022-06
  28. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  29. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  30. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological MalignanciesActive, not recruitingNCT04684108Study sitePhase 1Start 2021-11
  31. ATG-010(Selinexor) in Combination With Chemotherapy in RRMMStatus unknownNCT04877275Study sitePhase 2Start 2021-05
  32. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  33. A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory MyelomaTerminatedNCT04735575Study sitePhase 1/Phase 2Start 2021-05
  34. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Study sitePhase 1/Phase 2Start 2021-04
  35. A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple MyelomaStatus unknownNCT05271682Study sitePhase 1Start 2021-12
  36. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  37. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  38. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Study sitePhase 1/Phase 2Start 2020-04
  39. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  40. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  41. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  42. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  43. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  44. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03215030Study sitePhase 1/Phase 2Start 2017-10
  45. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  46. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  47. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  48. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyCompletedNCT02609828Study sitePhase 3Start 2015-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

3 hospitals in Zhengzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06450067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  2. Recruiting
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05579132

    Age 2 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 4 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 1.0%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 002025

2 hospitals in Zhengzhou for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplantChildren

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

8 hospitals in Zhengzhou for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06833983

    Age 18 years to 65 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led1
  1. Sequential combined bypassing therapy in haemophilia patients with high titer inhibitors: surgical experience.2025Annals of hematology
Earlier papers (2016–2020)2
  1. [Perioperative application of recombinant human coagulation factor Ⅶa combined with prothrombin complex in two hemophilia A patients with high titer inhibitor].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  2. [Post-transplantation lymphoproliferative disorder accompanies acquired hemophilia after haploid hematopoietic stem cell transplantation in a pediatric AML patient: a case report and literature review].2019Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
All its trials on ClinicalTrials.gov, any status10
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia ARecruitingNCT06833983Study sitePhase 3Start 2025-03
  2. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06
  3. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  4. Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with InhibitorCompletedNCT06289166Study sitePhase 2Start 2024-03
  5. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  6. Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without InhibitorCompletedNCT05619926Study sitePhase 2Start 2023-01
  7. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  8. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  9. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04061109Study sitePhase 3Start 2019-05
  10. Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04060836Study sitePhase 1Start 2019-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Zhengzhou for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

河南省肿瘤医院

Henan Cancer Hospital

郑州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital Affiliated to Zhengzhou University; Henan Cancer Hospital/Institute; Henan Cancer Hospital & Institute; Henan Cancer Hospital and Zhengzhou University Cancer Hospital; Cancer Hospital of Zhengzhou University and Henan Cancer Hospital

Suggest a correctionDownload the data